{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:28:12Z","timestamp":1786429692194,"version":"build-2736575974"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"DOI":"10.1186\/s40478-026-02335-6","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:25:02Z","timestamp":1780417502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polymeric lysosome-targeting chimeras for extracellular \u03b1-synuclein degradation in Parkinson\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Arghya","family":"Bhattacharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailah M.","family":"Almohaimeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waheeb Sami","family":"Aggad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany I.","family":"Almars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama Mohammed Abdulaziz","family":"Altowaijri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel Abdulrahman","family":"Waggas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuha M.","family":"Bauthman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair M.","family":"Mohammedsaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahani Ahmad","family":"ALMatrafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez M.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Ejim","family":"Uti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"3","key":"2335_CR1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tins.2014.12.009","volume":"38","author":"BH Hunn","year":"2015","unstructured":"Hunn BH, Cragg SJ, Bolam JP, Spillantini MG, Wade-Martins R (2015) Impaired intracellular trafficking defines early Parkinson\u2019s disease. Trends Neurosci 38(3):178\u2013188. https:\/\/doi.org\/10.1016\/j.tins.2014.12.009","journal-title":"Trends Neurosci"},{"key":"2335_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101613","volume":"31","author":"N Mukerjee","year":"2025","unstructured":"Mukerjee N, Bhattacharya A, Maitra S, Kaur M, Ganesan S, Mishra S, Ashraf A, Rizwan M, Kesari KK, Tabish TA, Thorat ND (2025) Exosome isolation and characterization for advanced diagnostic and therapeutic applications. Mater today Bio 31:101613. https:\/\/doi.org\/10.1016\/j.mtbio.2025.101613","journal-title":"Mater today Bio"},{"issue":"10","key":"2335_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107742","volume":"300","author":"A Bayati","year":"2024","unstructured":"Bayati A, McPherson PS (2024) Alpha-synuclein, autophagy-lysosomal pathway, and Lewy bodies: Mutations, propagation, aggregation, and the formation of inclusions. J Biol Chem [Internet]. 300(10):107742","journal-title":"J Biol Chem [Internet]."},{"issue":"8","key":"2335_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"B Dehay","year":"2015","unstructured":"Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S et al (2015) Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol 14(8):855\u2013866","journal-title":"Lancet Neurol"},{"key":"2335_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215312","author":"KJ Lin","year":"2019","unstructured":"Lin KJ, Lin KL, Chen SD, Liou CW, Chuang YC, Lin HY et al (2019) The overcrowded crossroads: mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System interaction in Parkinson\u2019s Disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20215312","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2335_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.devcel.2015.02.002","volume":"32","author":"J Lim","year":"2015","unstructured":"Lim J, Yue Z (2015) Neuronal aggregates: formation, clearance, and spreading. Dev Cell [Internet]. 32(4):491\u2013501","journal-title":"Dev Cell [Internet]."},{"issue":"1","key":"2335_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/tra.70026","volume":"27","author":"S Jiang","year":"2026","unstructured":"Jiang S, Fu J, Li S, Li Z, Zhao Q, Yin Y et al (2026) Unraveling lysosomal exocytosis: from molecular mechanisms to physiological functions. Traffic 27(1):e70026","journal-title":"Traffic"},{"key":"2335_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jns.2016.07.057","volume":"368","author":"SH Kang","year":"2016","unstructured":"Kang SH, Lee HM, Seo WK, Kim JH, Koh SB (2016) The combined effect of REM sleep behavior disorder and hyposmia on cognition and motor phenotype in Parkinson\u2019s disease. J Neurol Sci 368:374\u2013378","journal-title":"J Neurol Sci"},{"key":"2335_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105141","volume":"149","author":"Y Du","year":"2021","unstructured":"Du Y, Yang X, Li Z, Le W, Hao Y, Song Y et al (2021) HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy. Neurochem Int 149:105141","journal-title":"Neurochem Int"},{"key":"2335_CR10","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2025.5578","author":"F Qu","year":"2025","unstructured":"Qu F, Zhao Q, Jin Y (2025) Histone deacetylase 6: a new player in oxidative stress\u2011associated disorders and cancers (review). Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2025.5578","journal-title":"Int J Mol Med"},{"issue":"10","key":"2335_CR11","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1128\/MCB.05155-11","volume":"31","author":"EF de Zoeten","year":"2011","unstructured":"de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al (2011) Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) t-regulatory cells. Mol Cell Biol 31(10):2066\u20132078","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2335_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-021-00375-3","volume":"27","author":"P Liu","year":"2021","unstructured":"Liu P, Xiao J, Wang Y, Song X, Huang L, Ren Z et al (2021) Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90. Mol Med 27(1):110","journal-title":"Mol Med"},{"key":"2335_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010013","author":"N Paccione","year":"2022","unstructured":"Paccione N, Rahmani M, Barcia E, Negro S (2022) Antiparkinsonian agents in investigational polymeric micro- and nano-systems. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15010013","journal-title":"Pharmaceutics"},{"issue":"42","key":"2335_CR14","doi-asserted-by":"publisher","first-page":"17652","DOI":"10.1039\/D4SC05093B","volume":"15","author":"T Fang","year":"2024","unstructured":"Fang T, Zheng Z, Li N, Zhang Y, Ma J, Yun C et al (2024) Lysosome-targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins. Chem Sci 15(42):17652\u201317662","journal-title":"Chem Sci"},{"issue":"5","key":"2335_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bbapap.2018.09.012","volume":"1867","author":"EI O\u2019Leary","year":"2019","unstructured":"O\u2019Leary EI, Lee JC (2019) Interplay between \u03b1-synuclein amyloid formation and membrane structure. Biochim Biophys acta Proteins Proteomics 1867(5):483\u2013491","journal-title":"Biochim Biophys acta Proteins Proteomics"},{"issue":"1","key":"2335_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1021\/jacs.5c17519","volume":"148","author":"RHH Lu","year":"2026","unstructured":"Lu RHH, Krishna J, Alp Y, Thayumanavan S (2026) Polymeric Lysosome-Targeting Chimeras (PolyTACs): extracellular targeted protein degradation without co-opting lysosome-targeting receptors. J Am Chem Soc 148(1):1259\u20131270","journal-title":"J Am Chem Soc"},{"issue":"17","key":"2335_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308924","volume":"11","author":"Q Duan","year":"2024","unstructured":"Duan Q, Jia HR, Chen W, Qin C, Zhang K, Jia F et al (2024) Multivalent aptamer-based lysosome-targeting chimeras (LYTACs) platform for mono- or dual-targeted proteins degradation on cell surface. Adv Sci 11(17):e2308924","journal-title":"Adv Sci"},{"issue":"9","key":"2335_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","volume":"17","author":"G Ahn","year":"2021","unstructured":"Ahn G, Banik SM, Miller CL, Riley NM, Cochran JR, Bertozzi CR (2021) LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat Chem Biol 17(9):937\u2013946","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2335_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01703-4","volume":"18","author":"MAA Mamun","year":"2025","unstructured":"Mamun MAA, Bakunts AG, Chernorudskiy AL (2025) Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs. J Hematol Oncol 18(1):52","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2335_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70197","volume":"86","author":"S Asadi","year":"2025","unstructured":"Asadi S, Taheri-Torbati M, Kesharwani P, Sahebkar A (2025) Lysosome-mediated targeted protein degradation: emerging chimeric platforms for extracellular and intracellular therapeutics. Drug Dev Res 86(8):e70197","journal-title":"Drug Dev Res"},{"key":"2335_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-1-2","volume":"1","author":"NP Visanji","year":"2013","unstructured":"Visanji NP, Brooks PL, Hazrati LN, Lang AE (2013) The prion hypothesis in Parkinson\u2019s disease: braak to the future. Acta Neuropathol Commun 1:2","journal-title":"Acta Neuropathol Commun"},{"key":"2335_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00037","volume":"8","author":"CD Rietdijk","year":"2017","unstructured":"Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA, Kraneveld AD (2017) Exploring braak\u2019s hypothesis of Parkinson\u2019s disease. Front Neurol 8:37","journal-title":"Front Neurol"},{"key":"2335_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910783","author":"A Bougea","year":"2024","unstructured":"Bougea A (2024) Seeding aggregation assays in Lewy bodies disorders: a narrative state-of-the-art review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms251910783","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2335_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"issue":"2","key":"2335_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s12035-012-8267-8","volume":"47","author":"CM Lema Tom\u00e9","year":"2013","unstructured":"Lema Tom\u00e9 CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P (2013) Inflammation and \u03b1-synuclein\u2019s prion-like behavior in Parkinson\u2019s disease--is there a link? Mol Neurobiol 47(2):561\u2013574","journal-title":"Mol Neurobiol"},{"key":"2335_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bionps.2023.100074","volume":"9","author":"KY Yamashita","year":"2023","unstructured":"Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT (2023) Biomarkers in Parkinson\u2019s disease: a state of the art review. Biomark Neuropsych [Internet]. 9:100074","journal-title":"Biomark Neuropsych [Internet]."},{"issue":"5","key":"2335_CR27","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4103\/1673-5374.268893","volume":"15","author":"M Pascual","year":"2020","unstructured":"Pascual M, Ib\u00e1\u00f1ez F, Guerri C (2020) Exosomes as mediators of neuron-glia communication in neuroinflammation. Neural Regen Res 15(5):796\u2013801","journal-title":"Neural Regen Res"},{"issue":"1","key":"2335_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00651-2","volume":"19","author":"DJ Rinauro","year":"2024","unstructured":"Rinauro DJ, Chiti F, Vendruscolo M, Limbocker R (2024) Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases. Mol Neurodegener 19(1):20","journal-title":"Mol Neurodegener"},{"key":"2335_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105799","volume":"115","author":"CK Bhusal","year":"2023","unstructured":"Bhusal CK, Uti DE, Mukherjee D, Alqahtani T, Alqahtani S, Bhattacharya A et al (2023) Unveiling nature\u2019s potential: promising natural compounds in Parkinson\u2019s disease management. Parkinsonism Relat Disord 115:105799","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"2335_CR30","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s12035-020-02243-3","volume":"58","author":"F Currim","year":"2021","unstructured":"Currim F, Singh J, Shinde A, Gohel D, Roy M, Singh K et al (2021) Exosome release is modulated by the mitochondrial-lysosomal crosstalk in Parkinson\u2019s disease stress conditions. Mol Neurobiol 58(4):1819\u20131833","journal-title":"Mol Neurobiol"},{"issue":"1","key":"2335_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00622-7","volume":"18","author":"T Koeglsperger","year":"2023","unstructured":"Koeglsperger T, Rumpf SL, Schlie\u00dfer P, Struebing FL, Brendel M, Levin J et al (2023) Neuropathology of incidental Lewy body & prodromal Parkinson\u2019s disease. Mol Neurodegener 18(1):32","journal-title":"Mol Neurodegener"},{"issue":"2","key":"2335_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/mds.26421","volume":"31","author":"H McCann","year":"2016","unstructured":"McCann H, Cartwright H, Halliday GM (2016) Neuropathology of \u03b1-synuclein propagation and braak hypothesis. Mov Disord 31(2):152\u2013160","journal-title":"Mov Disord"},{"issue":"2","key":"2335_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","volume":"1822","author":"L Breydo","year":"2012","unstructured":"Breydo L, Wu JW, Uversky VN (2012) \u03b1-Synuclein misfolding and Parkinson\u2019s disease. Biochim Biophys Acta - Mol Basis Dis [Internet]. 1822(2):261\u2013285","journal-title":"Biochim Biophys Acta - Mol Basis Dis [Internet]."},{"issue":"12","key":"2335_CR34","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1089\/ars.2011.4501","volume":"17","author":"A Garcia-Garcia","year":"2012","unstructured":"Garcia-Garcia A, Zavala-Flores L, Rodriguez-Rocha H, Franco R (2012) Thiol-redox signaling, dopaminergic cell death, and Parkinson\u2019s disease. Antioxid Redox Signal 17(12):1764\u20131784","journal-title":"Antioxid Redox Signal"},{"issue":"11","key":"2335_CR35","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/glia.24244","volume":"70","author":"BM Bradford","year":"2022","unstructured":"Bradford BM, McGuire LI, Hume DA, Pridans C, Mabbott NA (2022) Microglia deficiency accelerates prion disease but does not enhance prion accumulation in the brain. Glia 70(11):2169\u20132187","journal-title":"Glia"},{"key":"2335_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181169","author":"N Makarava","year":"2024","unstructured":"Makarava N, Safadi T, Bocharova O, Mychko O, Pandit NP, Molesworth K et al (2024) Reactive microglia partially envelop viable neurons in prion diseases. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI181169","journal-title":"J Clin Invest"},{"key":"2335_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/v11010065","author":"JA Carroll","year":"2019","unstructured":"Carroll JA, Chesebro B (2019) Neuroinflammation, microglia, and cell-association during prion disease. Viruses. https:\/\/doi.org\/10.3390\/v11010065","journal-title":"Viruses"},{"issue":"6","key":"2335_CR38","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1084\/jem.20151000","volume":"213","author":"C Zhu","year":"2016","unstructured":"Zhu C, Herrmann US, Falsig J, Abakumova I, Nuvolone M, Schwarz P et al (2016) A neuroprotective role for microglia in prion diseases. J Exp Med 213(6):1047\u20131059","journal-title":"J Exp Med"},{"issue":"1","key":"2335_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/19336896.2021.1991771","volume":"15","author":"ASLF de Melo","year":"2021","unstructured":"de Melo ASLF, Lima JLD, Malta MCS, Marroquim NF, Moreira \u00c1R, de Almeida Ladeia I et al (2021) The role of microglia in prion diseases and possible therapeutic targets: a literature review. Prion 15(1):191\u2013206","journal-title":"Prion"},{"key":"2335_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186940","author":"VA Lawson","year":"2024","unstructured":"Lawson VA (2024) Supportive care or exhausted neglect: the role of microglia at the end stage of prion disease. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI186940","journal-title":"J Clin Invest"},{"issue":"5","key":"2335_CR41","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1021\/acsomega.3c08305","volume":"9","author":"K Das","year":"2024","unstructured":"Das K, Balaram H, Sanyal K (2024) Amino acid chirality: stereospecific conversion and physiological implications. ACS Omega 9(5):5084\u20135099. https:\/\/doi.org\/10.1021\/acsomega.3c08305","journal-title":"ACS Omega"},{"key":"2335_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110173","volume":"367","author":"K Jomova","year":"2022","unstructured":"Jomova K, Makova M, Alomar SY, Alwasel SH, Nepovimova E, Kuca K et al (2022) Essential metals in health and disease. Chem Biol Interact [Internet]. 367:110173","journal-title":"Chem Biol Interact [Internet]."},{"issue":"45","key":"2335_CR43","doi-asserted-by":"publisher","first-page":"42045","DOI":"10.1021\/acsomega.3c04862","volume":"8","author":"J Burns","year":"2023","unstructured":"Burns J, Buck AC, D\u2019 Souza S, Dube A, Bardien S (2023) Nanophytomedicines as therapeutic agents for Parkinson\u2019s disease. ACS Omega 8(45):42045\u201342061. https:\/\/doi.org\/10.1021\/acsomega.3c04862","journal-title":"ACS Omega"},{"issue":"1","key":"2335_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1021\/cn500256e","volume":"6","author":"TDY Kozai","year":"2015","unstructured":"Kozai TDY, Jaquins-Gerstl AS, Vazquez AL, Michael AC, Cui XT (2015) Brain tissue responses to neural implants impact signal sensitivity and intervention strategies. ACS Chem Neurosci 6(1):48\u201367. https:\/\/doi.org\/10.1021\/cn500256e","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"2335_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/NRR.NRR-D-23-01195","volume":"20","author":"F Jiao","year":"2025","unstructured":"Jiao F, Meng L, Du K, Li X (2025) The autophagy-lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson\u2019s disease. Neural Regen Res 20(1):139\u2013158","journal-title":"Neural Regen Res"},{"issue":"1","key":"2335_CR46","first-page":"6","volume":"5","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang H, Dong J, Cai H, Le W (2025) Advances in autophagy for Parkinson\u2019s disease pathogenesis and treatment. Ageing Neurodegener Dis. 5(1):6","journal-title":"Ageing Neurodegener Dis."},{"key":"2335_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123547","author":"SR Bonam","year":"2021","unstructured":"Bonam SR, Tranchant C, Muller S (2021) Autophagy-lysosomal pathway as potential therapeutic target in Parkinson\u2019s disease. Cells. https:\/\/doi.org\/10.3390\/cells10123547","journal-title":"Cells"},{"issue":"8","key":"2335_CR48","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","volume":"432","author":"X Hou","year":"2020","unstructured":"Hou X, Watzlawik JO, Fiesel FC, Springer W (2020) Autophagy in Parkinson\u2019s disease. J Mol Biol 432(8):2651\u20132672","journal-title":"J Mol Biol"},{"issue":"1","key":"2335_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0154-3","volume":"12","author":"TE Moors","year":"2017","unstructured":"Moors TE, Hoozemans JJM, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC et al (2017) Therapeutic potential of autophagy-enhancing agents in Parkinson\u2019s disease. Mol Neurodegener 12(1):11","journal-title":"Mol Neurodegener"},{"key":"2335_CR50","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2147\/IDR.S254403","volume":"13","author":"W Tang","year":"2020","unstructured":"Tang W, Zhu H, Feng Y, Guo R, Wan D (2020) The impact of gut microbiota disorders on the blood-brain barrier. Infect Drug Resist 13:3351\u20133363","journal-title":"Infect Drug Resist"},{"key":"2335_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2014.08.007","volume":"44","author":"WA Banks","year":"2015","unstructured":"Banks WA (2015) The blood-brain barrier in neuroimmunology: tales of separation and assimilation. Brain Behav Immun 44:1\u20138","journal-title":"Brain Behav Immun"},{"issue":"2","key":"2335_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1535370217743766","volume":"243","author":"AF Logsdon","year":"2018","unstructured":"Logsdon AF, Erickson MA, Rhea EM, Salameh TS, Banks WA (2018) Gut reactions: how the blood-brain barrier connects the microbiome and the brain. Exp Biol Med (Maywood) 243(2):159\u2013165","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"2335_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202100270","volume":"23","author":"Z Hu","year":"2022","unstructured":"Hu Z, Crews CM (2022) Recent developments in PROTAC-mediated protein degradation: from bench to clinic. ChemBioChem 23(2):e202100270","journal-title":"ChemBioChem"},{"issue":"2","key":"2335_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang X, Feng F, Liu W, Sun H (2020) Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B 10(2):207\u2013238","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"2335_CR55","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li K, Crews CM (2022) PROTACs: past, present and future. Chem Soc Rev 51(12):5214\u20135236","journal-title":"Chem Soc Rev"},{"issue":"7","key":"2335_CR56","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.chembiol.2021.02.024","volume":"28","author":"G Ahn","year":"2021","unstructured":"Ahn G, Banik SM, Bertozzi CR (2021) Degradation from the outside in: targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Cell Chem Biol 28(7):1072\u20131080","journal-title":"Cell Chem Biol"},{"issue":"9","key":"2335_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29926","volume":"96","author":"N Mukerjee","year":"2024","unstructured":"Mukerjee N, Maitra S, Mukherjee D, Ghosh A, Alexiou AT, Thorat ND (2024) Harnessing PROTACs to combat H5N1 influenza: a new frontier in viral destruction. J Med Virol 96(9):e29926. https:\/\/doi.org\/10.1002\/jmv.29926","journal-title":"J Med Virol"},{"issue":"17","key":"2335_CR58","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.7150\/thno.62686","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin J, Jin J, Shen Y, Zhang L, Gong G, Bian H et al (2021) Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics 11(17):8337\u20138349","journal-title":"Theranostics"},{"issue":"1","key":"2335_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22145","volume":"85","author":"N Mukerjee","year":"2024","unstructured":"Mukerjee N, Maitra S, Sharma R (2024) Proteolysis-targeting chimeras in antiviral therapy: leveraging influenza virus and exosome-mediated delivery for targeted protein degradation and therapeutic advancements. Drug Dev Res 85(1):e22145","journal-title":"Drug Dev Res"},{"issue":"12","key":"2335_CR60","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1039\/D2MD00273F","volume":"13","author":"S Ghosh","year":"2022","unstructured":"Ghosh S, Ramadas B, Manna D (2022) Targeted protein degradation using the lysosomal pathway. RSC Med Chem 13(12):1476\u20131494","journal-title":"RSC Med Chem"},{"key":"2335_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100647","volume":"296","author":"SB Alabi","year":"2021","unstructured":"Alabi SB, Crews CM (2021) Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J Biol Chem 296:100647","journal-title":"J Biol Chem"},{"issue":"32","key":"2335_CR62","doi-asserted-by":"publisher","first-page":"8433","DOI":"10.1039\/D3SC02361C","volume":"14","author":"F Shen","year":"2023","unstructured":"Shen F, Dassama LMK (2023) Opportunities and challenges of protein-based targeted protein degradation. Chem Sci 14(32):8433\u20138447","journal-title":"Chem Sci"},{"issue":"8","key":"2335_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28981","volume":"95","author":"N Mukerjee","year":"2023","unstructured":"Mukerjee N, Ghosh A (2023) Revolutionizing viral disease treatment: PROTACs therapy could be the ultimate weapon of the future. J Med Virol 95(8):e28981","journal-title":"J Med Virol"},{"key":"2335_CR64","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/bs.pmbts.2020.06.001","volume":"174","author":"AA Bhopatkar","year":"2020","unstructured":"Bhopatkar AA, Uversky VN, Rangachari V (2020) Disorder and cysteines in proteins: a design for orchestration of conformational see-saw and modulatory functions. Prog Mol Biol Transl Sci 174:331\u2013373","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5","key":"2335_CR65","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.tips.2018.02.007","volume":"39","author":"BD Paul","year":"2018","unstructured":"Paul BD, Sbodio JI, Snyder SH (2018) Cysteine metabolism in neuronal redox homeostasis. Trends Pharmacol Sci 39(5):513\u2013524","journal-title":"Trends Pharmacol Sci"},{"key":"2335_CR66","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/jacsau.1c00128","volume":"6","author":"Q Laurent","year":"2021","unstructured":"Laurent Q, Martinent R, Lim B, Pham AT, Kato T, L\u00f3pez-Andarias J et al (2021) Thiol-mediated uptake. JACS Au [Internet]. 6:710\u2013728. https:\/\/doi.org\/10.1021\/jacsau.1c00128","journal-title":"JACS Au [Internet]."},{"key":"2335_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.788128","volume":"10","author":"SA Annu","year":"2022","unstructured":"Annu SA, Qamar Z, Md S, Alhakamy NA, Baboota S et al (2022) An insight to brain targeting utilizing polymeric nanoparticles: effective treatment modalities for neurological disorders and brain tumor. Front Bioeng Biotechnol. 10:788128","journal-title":"Front Bioeng Biotechnol."},{"key":"2335_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.112999","volume":"221","author":"MI Teixeira","year":"2023","unstructured":"Teixeira MI, Lopes CM, Amaral MH, Costa PC (2023) Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surfaces B Biointerfaces [Internet]. 221:112999","journal-title":"Colloids Surfaces B Biointerfaces [Internet]."},{"issue":"8","key":"2335_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13804","volume":"58","author":"L Jin","year":"2025","unstructured":"Jin L, Nie L, Deng Y, Khana GJ, He N (2025) The application of polymeric nanoparticles as drug delivery carriers to cells in neurodegenerative diseases. Cell Prolif 58(8):e13804","journal-title":"Cell Prolif"},{"issue":"1","key":"2335_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"B Wang","year":"2024","unstructured":"Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y et al (2024) Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther 9(1):200. https:\/\/doi.org\/10.1038\/s41392-024-01889-y","journal-title":"Signal Transduct Target Ther"},{"issue":"46","key":"2335_CR71","doi-asserted-by":"publisher","first-page":"54621","DOI":"10.1021\/acsami.1c13634","volume":"13","author":"H Wang","year":"2021","unstructured":"Wang H, Gao L, Fan T, Zhang C, Zhang B, Al-Hartomy OA et al (2021) Strategic design of intelligent-responsive nanogel carriers for cancer therapy. ACS Appl Mater Interfaces 13(46):54621\u201354647. https:\/\/doi.org\/10.1021\/acsami.1c13634","journal-title":"ACS Appl Mater Interfaces"},{"issue":"22","key":"2335_CR72","doi-asserted-by":"publisher","first-page":"11118","DOI":"10.1021\/acs.chemrev.7b00660","volume":"118","author":"MJ Limo","year":"2018","unstructured":"Limo MJ, Sola-Rabada A, Boix E, Thota V, Westcott ZC, Puddu V et al (2018) Interactions between metal oxides and biomolecules: from fundamental understanding to applications. Chem Rev 118(22):11118\u201311193. https:\/\/doi.org\/10.1021\/acs.chemrev.7b00660","journal-title":"Chem Rev"},{"issue":"1","key":"2335_CR73","doi-asserted-by":"publisher","DOI":"10.1088\/1478-3975\/aa5788","volume":"14","author":"J Chin","year":"2017","unstructured":"Chin J, Mustafi D, Poellmann MJ, Lee RC (2017) Amphiphilic copolymers reduce aggregation of unfolded lysozyme more effectively than polyethylene glycol. Phys Biol 14(1):16003","journal-title":"Phys Biol"},{"key":"2335_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114683","volume":"197","author":"M Placci","year":"2023","unstructured":"Placci M, Giannotti MI, Muro S (2023) Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders. Adv Drug Deliv Rev 197:114683","journal-title":"Adv Drug Deliv Rev"},{"key":"2335_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpolymj.2022.111030","volume":"166","author":"ZH Zhang","year":"2022","unstructured":"Zhang ZH, Li CC, Cui WL, Qu J, Zhang H, Liu K et al (2022) A novel and modified fluorescent amphiphilic block copolymer simultaneously targeting to lysosomes and lipid droplets for cell imaging with large Stokes shift. Eur Polym J [Internet]. 166:111030","journal-title":"Eur Polym J [Internet]."},{"key":"2335_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2025.106136","volume":"131","author":"H Sun","year":"2026","unstructured":"Sun H, Xie X, Li Y, Zhu W, Hou Y, Xie H et al (2026) Function and mechanism of dopamine receptor D2 (DRD2) in neuroinflammation and behavioral disorders in C57BL\/6J mice infected with Toxoplasma gondii TgCtWh6 strain. Brain Behav Immun [Internet]. 131:106136","journal-title":"Brain Behav Immun [Internet]."},{"issue":"35","key":"2335_CR77","doi-asserted-by":"publisher","first-page":"22008","DOI":"10.1021\/acsomega.0c01249","volume":"5","author":"U Malik","year":"2020","unstructured":"Malik U, Zafar S, Younas N, Zerr I, Javed A (2020) Unveiling the physical and functional niches of FAM26F by analyzing its subcellular localization and novel interacting partners. ACS Omega 5(35):22008\u201322020. https:\/\/doi.org\/10.1021\/acsomega.0c01249","journal-title":"ACS Omega"},{"issue":"3","key":"2335_CR78","first-page":"137","volume":"17","author":"Z Khan","year":"2018","unstructured":"Khan Z, Ali SA (2018) Oxidative stress-related biomarkers in Parkinson\u2019s disease: a systematic review and meta-analysis. Iran J Neurol 17(3):137\u2013144","journal-title":"Iran J Neurol"},{"issue":"20","key":"2335_CR79","doi-asserted-by":"publisher","first-page":"11849","DOI":"10.1021\/acsomega.0c01818","volume":"5","author":"B Salehi","year":"2020","unstructured":"Salehi B, Machin L, Monzote L, Sharifi-Rad J, Ezzat SM, Salem MA et al (2020) Therapeutic potential of Quercetin: new insights and perspectives for human health. ACS Omega 5(20):11849\u201311872. https:\/\/doi.org\/10.1021\/acsomega.0c01818","journal-title":"ACS Omega"},{"issue":"4","key":"2335_CR80","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JPD-130230","volume":"3","author":"V Dias","year":"2013","unstructured":"Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson\u2019s disease. J Parkinsons Dis 3(4):461\u2013491","journal-title":"J Parkinsons Dis"},{"key":"2335_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115222","volume":"165","author":"H Liang","year":"2023","unstructured":"Liang H, Zhang L, Rong J (2023) Potential roles of exosomes in the initiation and metastatic progression of lung cancer. Biomed Pharmac [Internet]. 165:115222","journal-title":"Biomed Pharmac [Internet]."},{"issue":"6","key":"2335_CR82","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11306-024-02181-4","volume":"20","author":"X Flores-Ponce","year":"2024","unstructured":"Flores-Ponce X, Velasco I (2024) Dopaminergic neuron metabolism: relevance for understanding Parkinson\u2019s disease. Metabolomics 20(6):116","journal-title":"Metabolomics"},{"issue":"8","key":"2335_CR83","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.3390\/ijms160819458","volume":"16","author":"JM Ross","year":"2015","unstructured":"Ross JM, Olson L, Coppotelli G (2015) Mitochondrial and ubiquitin proteasome system dysfunction in ageing and disease: two sides of the same coin? Int J Mol Sci 16(8):19458\u201319476","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2335_CR84","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","volume":"24","author":"HE Moon","year":"2015","unstructured":"Moon HE, Paek SH (2015) Mitochondrial dysfunction in parkinson\u2019s disease. Exp Neurobiol 24(2):103\u2013116","journal-title":"Exp Neurobiol"},{"key":"2335_CR85","first-page":"9163040","volume":"2018","author":"M Weng","year":"2018","unstructured":"Weng M, Xie X, Liu C, Lim KL, Zhang CW, Li L (2018) The sources of reactive oxygen species and its possible role in the pathogenesis of parkinson\u2019s disease. Parkinsons Dis 2018:9163040","journal-title":"Parkinsons Dis"},{"key":"2335_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2024.110133","volume":"260","author":"H Chen","year":"2024","unstructured":"Chen H, Li J, Huang Z, Fan X, Wang X, Chen X et al (2024) Dopaminergic system and neurons: role in multiple neurological diseases. Neuropharmacology [Internet]. 260:110133","journal-title":"Neuropharmacology [Internet]."},{"issue":"1","key":"2335_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01353-3","volume":"8","author":"X Dong-Chen","year":"2023","unstructured":"Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P (2023) Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):73. https:\/\/doi.org\/10.1038\/s41392-023-01353-3","journal-title":"Signal Transduct Target Ther"},{"issue":"24 Pt A","key":"2335_CR88","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1016\/j.febslet.2015.10.021","volume":"589","author":"D Haddad","year":"2015","unstructured":"Haddad D, Nakamura K (2015) Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson\u2019s disease. FEBS Lett 589(24 Pt A):3702\u20133713","journal-title":"FEBS Lett"},{"issue":"1","key":"2335_CR89","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/tx700210j","volume":"21","author":"LM Sayre","year":"2008","unstructured":"Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21(1):172\u2013188. https:\/\/doi.org\/10.1021\/tx700210j","journal-title":"Chem Res Toxicol"},{"key":"2335_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125186","volume":"670","author":"Z Sadat Razavi","year":"2025","unstructured":"Sadat Razavi Z, Sina Alizadeh S, Sadat Razavi F, Souri M, Soltani M (2025) Advancing neurological disorders therapies: Organic nanoparticles as a key to blood-brain barrier penetration. Int J Pharm [Internet]. 670:125186","journal-title":"Int J Pharm [Internet]."},{"issue":"1","key":"2335_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-017-0099-z","volume":"6","author":"P Maiti","year":"2017","unstructured":"Maiti P, Manna J, Dunbar GL (2017) Current understanding of the molecular mechanisms in Parkinson\u2019s disease: targets for potential treatments. Transl Neurodegener 6(1):28. https:\/\/doi.org\/10.1186\/s40035-017-0099-z","journal-title":"Transl Neurodegener"},{"issue":"5","key":"2335_CR92","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/mol.117.109926","volume":"92","author":"AM Gleixner","year":"2017","unstructured":"Gleixner AM, Hutchison DF, Sannino S, Bhatia TN, Leak LC, Flaherty PT et al (2017) N-Acetyl-l-cysteine protects astrocytes against proteotoxicity without recourse to glutathione. Mol Pharmacol 92(5):564\u2013575","journal-title":"Mol Pharmacol"},{"issue":"3","key":"2335_CR93","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci [Internet]. 144(3):151\u2013164","journal-title":"J Pharmacol Sci [Internet]."},{"issue":"1","key":"2335_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01298-z","volume":"8","author":"ZG Lu","year":"2023","unstructured":"Lu ZG, Shen J, Yang J, Wang JW, Zhao RC, Zhang TL et al (2023) Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduct Target Ther 8(1):39. https:\/\/doi.org\/10.1038\/s41392-022-01298-z","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2335_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01526-9","volume":"11","author":"JM Lawrence","year":"2023","unstructured":"Lawrence JM, Schardien K, Wigdahl B, Nonnemacher MR (2023) Roles of neuropathology-associated reactive astrocytes: a systematic review. Acta Neuropathol Commun 11(1):42. https:\/\/doi.org\/10.1186\/s40478-023-01526-9","journal-title":"Acta Neuropathol Commun"},{"key":"2335_CR96","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19998","volume":"13","author":"Z Li","year":"2025","unstructured":"Li Z, Cao M, Yin Z, Li X, Wang Q, Dong P et al (2025) Functional characteristics, intercellular interactions and pathophysiological associations of astrocytes in Parkinson\u2019s disease. PeerJ 13:e19998","journal-title":"PeerJ"},{"key":"2335_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116558","volume":"350","author":"LC Dury","year":"2025","unstructured":"Dury LC, Yde Ohki CM, Lesch KP, Walitza S, Gr\u00fcnblatt E (2025) The role of astrocytes in attention-deficit hyperactivity disorder: an update. Psychiatry Res [Internet]. 350:116558","journal-title":"Psychiatry Res [Internet]."},{"issue":"1","key":"2335_CR98","volume":"13","author":"YG Lee","year":"2021","unstructured":"Lee YG, Jeon S, Kang SW, Park M, Baik K, Yoo HS et al (2021) Interaction of CSF \u03b1-synuclein and amyloid beta in cognition and cortical atrophy. Alzheimer\u2019s Dement (Amsterdam, Netherlands) 13(1):e12177","journal-title":"Alzheimer\u2019s Dement (Amsterdam, Netherlands)"},{"issue":"12","key":"2335_CR99","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1039\/c1ib00018g","volume":"3","author":"MR Sierks","year":"2011","unstructured":"Sierks MR, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S (2011) CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb) 3(12):1188\u20131196","journal-title":"Integr Biol (Camb)"},{"issue":"1","key":"2335_CR100","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41531-024-00854-4","volume":"11","author":"A Droby","year":"2025","unstructured":"Droby A, Yoffe-Vasiliev A, Atias D, Fraser KB, Mabrouk OS, Omer N et al (2025) Radiological markers of CSF \u03b1-synuclein aggregation in Parkinson\u2019s disease patients. NPJ Park Dis 11(1):7","journal-title":"NPJ Park Dis"},{"issue":"5","key":"2335_CR101","first-page":"1588","volume":"19","author":"F Rofo","year":"2022","unstructured":"Rofo F, Meier SR, Metzendorf NG, Morrison JI, Petrovic A, Syv\u00e4nen S et al (2022) A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in alzheimer\u2019s disease mice. Neurother J Am Soc Exp Neurother 19(5):1588\u20131602","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"2335_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB et al (2016) Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol Neurodegener 11:7","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2335_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65035-8","volume":"10","author":"V Gupta","year":"2020","unstructured":"Gupta V, Salim S, Hmila I, Vaikath NN, Sudhakaran IP, Ghanem SS et al (2020) Fibrillar form of \u03b1-synuclein-specific scFv antibody inhibits \u03b1-synuclein seeds induced aggregation and toxicity. Sci Rep 10(1):8137","journal-title":"Sci Rep"},{"issue":"2","key":"2335_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00510","volume":"22","author":"D Sehlin","year":"2025","unstructured":"Sehlin D, Roshanbin S, Zachrisson O, Ingelsson M, Syv\u00e4nen S (2025) A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology. Neurotherapeutics 22(2):e00510","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2335_CR105","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","volume":"1824","author":"V Turk","year":"2012","unstructured":"Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B et al (2012) Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim Biophys Acta 1824(1):68\u201388","journal-title":"Biochim Biophys Acta"},{"key":"2335_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071679","author":"T Yadati","year":"2020","unstructured":"Yadati T, Houben T, Bitorina A, Shiri-Sverdlov R (2020) The ins and outs of cathepsins: physiological function and role in disease management. Cells. https:\/\/doi.org\/10.3390\/cells9071679","journal-title":"Cells"},{"issue":"10","key":"2335_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29135","volume":"95","author":"N Mukerjee","year":"2023","unstructured":"Mukerjee N, Maitra S, Gorai S, Ghosh A, Alexiou A, Thorat ND (2023) Revolutionizing Human papillomavirus (HPV)-related cancer therapies: unveiling the promise of Proteolysis Targeting Chimeras (PROTACs) and Proteolysis Targeting Antibodies (PROTABs) in cancer nano-vaccines. J Med Virol 95(10):e29135. https:\/\/doi.org\/10.1002\/jmv.29135","journal-title":"J Med Virol"},{"issue":"12","key":"2335_CR108","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41423-025-01368-6","volume":"22","author":"T Shimizu","year":"2025","unstructured":"Shimizu T, Prinz M (2025) Microglia across evolution: from conserved origins to functional divergence. Cell Mol Immunol 22(12):1533\u20131548. https:\/\/doi.org\/10.1038\/s41423-025-01368-6","journal-title":"Cell Mol Immunol"},{"key":"2335_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122426","volume":"305","author":"A Proc\u00e8s","year":"2024","unstructured":"Proc\u00e8s A, Alpizar YA, Halliez S, Br\u00f4ne B, Saudou F, Ris L et al (2024) Stretch-injury promotes microglia activation with enhanced phagocytic and synaptic stripping activities. Biomaterials [Internet]. 305:122426","journal-title":"Biomaterials [Internet]."},{"key":"2335_CR110","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","volume":"35","author":"M Colonna","year":"2017","unstructured":"Colonna M, Butovsky O (2017) Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 35:441\u2013468","journal-title":"Annu Rev Immunol"},{"issue":"21","key":"2335_CR111","doi-asserted-by":"publisher","first-page":"11718","DOI":"10.1021\/acs.chemrev.5b00263","volume":"115","author":"J Mei","year":"2015","unstructured":"Mei J, Leung NLC, Kwok RTK, Lam JWY, Tang BZ (2015) Aggregation-induced emission: together we shine, united we soar! Chem Rev 115(21):11718\u201311940. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00263","journal-title":"Chem Rev"},{"key":"2335_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101613","volume":"31","author":"N Mukerjee","year":"2025","unstructured":"Mukerjee N, Bhattacharya A, Maitra S, Kaur M, Ganesan S, Mishra S et al (2025) Exosome isolation and characterization for advanced diagnostic and therapeutic applications. Mater Today Bio 31:101613","journal-title":"Mater Today Bio"},{"issue":"5","key":"2335_CR113","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/glia.23959","volume":"69","author":"S Salvany","year":"2021","unstructured":"Salvany S, Casanovas A, Piedrafita L, Tarabal O, Hern\u00e1ndez S, Calder\u00f3 J et al (2021) Microglial recruitment and mechanisms involved in the disruption of afferent synaptic terminals on spinal cord motor neurons after acute peripheral nerve injury. Glia 69(5):1216\u20131240","journal-title":"Glia"},{"key":"2335_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101117","volume":"27","author":"E Petillo","year":"2024","unstructured":"Petillo E, Veneruso V, Gragnaniello G, Brochier L, Frigerio E, Perale G et al (2024) Targeted therapy and deep learning insights into microglia modulation for spinal cord injury. Mater Today Bio 27:101117","journal-title":"Mater Today Bio"},{"issue":"1","key":"2335_CR115","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/NRR.NRR-D-24-00810","volume":"21","author":"L Shi","year":"2026","unstructured":"Shi L, Liu S, Chen J, Wang H, Wang Z (2026) Microglial polarization pathways and therapeutic drugs targeting activated microglia in traumatic brain injury. Neural Regen Res 21(1):39\u201356","journal-title":"Neural Regen Res"},{"issue":"7","key":"2335_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115929","volume":"44","author":"K Baid","year":"2025","unstructured":"Baid K, Shrivastava S, Luc J, Richard D, Aguiar JA, Machado Y et al (2025) Early innate immune response and evolution of a SARS-CoV-2 furin cleavage site inactive variant in bat cells. Cell Rep [Internet]. 44(7):115929","journal-title":"Cell Rep [Internet]."},{"issue":"18","key":"2335_CR117","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1021\/acs.chemrev.6b00169","volume":"116","author":"JM Pietryga","year":"2016","unstructured":"Pietryga JM, Park YS, Lim J, Fidler AF, Bae WK, Brovelli S et al (2016) Spectroscopic and device aspects of nanocrystal quantum dots. Chem Rev 116(18):10513\u201310622. https:\/\/doi.org\/10.1021\/acs.chemrev.6b00169","journal-title":"Chem Rev"},{"key":"2335_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.focha.2022.100108","volume":"1","author":"JD Kottawa-Arachchi","year":"2022","unstructured":"Lu RH, Krishna J, Alp Y, Thayumanavan S. Polymeric Lysosome-Targeting Chimeras (PolyTACs): Extracellular Targeted Protein Degradation without Co-Opting Lysosome-Targeting Receptors. J Am Chem Soc. 2026 Jan 14;148(1):1259-1270. doi: 10.1021\/jacs.5c17519. Epub 2026 Jan 2.","journal-title":"Food Chem Adv [Internet]."},{"issue":"11","key":"2335_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2025.100274","volume":"48","author":"TY Kim","year":"2025","unstructured":"Kim TY, Lee BD (2025) Current therapeutic strategies in Parkinson\u2019s disease: future perspectives. Mol Cells 48(11):100274","journal-title":"Mol Cells"},{"issue":"10","key":"2335_CR120","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1097\/MS9.0000000000001142","volume":"85","author":"P Prajjwal","year":"2023","unstructured":"Prajjwal P, Flores Sanga HS, Acharya K, Tango T, John J, Rodriguez RSC et al (2023) Parkinson\u2019s disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment. Ann Med Surg 85(10):4887\u20134902","journal-title":"Ann Med Surg"},{"key":"2335_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020371","author":"NA Gouda","year":"2022","unstructured":"Gouda NA, Elkamhawy A, Cho J (2022) Emerging therapeutic strategies for Parkinson\u2019s disease and future prospects: a 2021 update. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10020371","journal-title":"Biomedicines"},{"key":"2335_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040338","author":"J Ol\u00e1h","year":"2024","unstructured":"Ol\u00e1h J, Norris V, Lehotzky A, Ov\u00e1di J (2024) Perspective strategies for interventions in parkinsonism: remedying the neglected role of TPPP. Cells. https:\/\/doi.org\/10.3390\/cells13040338","journal-title":"Cells"},{"issue":"9","key":"2335_CR123","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71197","volume":"8","author":"MSB Faheem","year":"2025","unstructured":"Faheem MSB, Haroon-Ul-Rasheed M, Aftab R, Faheem Q, Feroze F, Ain HQU et al (2025) The next frontier in Parkinson\u2019s disease treatment: a narrative review of innovative neurosurgical and gene therapy approaches. Heal Sci reports 8(9):e71197","journal-title":"Heal Sci reports"},{"key":"2335_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00004","volume":"12","author":"A Iarkov","year":"2020","unstructured":"Iarkov A, Barreto GE, Grizzell JA, Echeverria V (2020) Strategies for the treatment of Parkinson\u2019s disease: beyond dopamine. Front Aging Neurosci 12:4","journal-title":"Front Aging Neurosci"},{"key":"2335_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060904","author":"S Sarkar","year":"2016","unstructured":"Sarkar S, Raymick J, Imam S (2016) Neuroprotective and therapeutic strategies against Parkinson\u2019s disease: recent perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms17060904","journal-title":"Int J Mol Sci"},{"key":"2335_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1431079","volume":"17","author":"CL Mitchell","year":"2024","unstructured":"Mitchell CL, Kurouski D (2024) Novel strategies in Parkinson\u2019s disease treatment: a review. Front Mol Neurosci 17:1431079","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"2335_CR127","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s13346-021-00963-0","volume":"11","author":"P Wei","year":"2021","unstructured":"Wei P, Cornel EJ, Du J (2021) Ultrasound-responsive polymer-based drug delivery systems. Drug Deliv Transl Res 11(4):1323\u20131339","journal-title":"Drug Deliv Transl Res"},{"key":"2335_CR128","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231211472","volume":"22","author":"M Kashkooli","year":"2023","unstructured":"Kashkooli M, Jakhmola A, Ferrier GA, Hornsby TK, Tavakkoli JJ, Kolios MC (2023) Integrating therapeutic ultrasound with nanosized drug delivery systems in the battle against cancer. Technol Cancer Res Treat 22:15330338231211472","journal-title":"Technol Cancer Res Treat"},{"key":"2335_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultsonch.2025.107557","volume":"124","author":"L Lai","year":"2026","unstructured":"Lai L, Han X, Tang Y, Zhou J, Cui W (2026) Advances in ultrasound-assisted drug delivery and clinical application. Ultrason Sonochem 124:107557","journal-title":"Ultrason Sonochem"},{"key":"2335_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultsonch.2021.105805","volume":"80","author":"S Shin Low","year":"2021","unstructured":"Shin Low S, Nong Lim C, Yew M, Siong Chai W, Low LE, Manickam S et al (2021) Recent ultrasound advancements for the manipulation of nanobiomaterials and nanoformulations for drug delivery. Ultrason Sonochem 80:105805","journal-title":"Ultrason Sonochem"},{"issue":"1","key":"2335_CR131","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17425247.2024.2438188","volume":"22","author":"CF Chuang","year":"2025","unstructured":"Chuang CF, Phan TN, Fan CH, Vo Le TT, Yeh CK (2025) Advancements in ultrasound-mediated drug delivery for Central Nervous System disorders. Expert Opin Drug Deliv 22(1):15\u201330","journal-title":"Expert Opin Drug Deliv"},{"key":"2335_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115199","volume":"206","author":"A Bouakaz","year":"2024","unstructured":"Bouakaz A, Michel EJ (2024) From concept to early clinical trials: 30 years of microbubble-based ultrasound-mediated drug delivery research. Adv Drug Deliv Rev [Internet]. 206:115199","journal-title":"Adv Drug Deliv Rev [Internet]."},{"issue":"1","key":"2335_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01464-z","volume":"20","author":"S Zhang","year":"2022","unstructured":"Zhang S, Zhang S, Luo S, Tang P, Wan M, Wu D et al (2022) Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect. J Nanobiotechnol 20(1):287. https:\/\/doi.org\/10.1186\/s12951-022-01464-z","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2335_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55294-5","volume":"9","author":"R Ji","year":"2019","unstructured":"Ji R, Smith M, Niimi Y, Karakatsani ME, Murillo MF, Jackson-Lewis V et al (2019) Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson\u2019s disease mouse model. Sci Rep 9(1):19402. https:\/\/doi.org\/10.1038\/s41598-019-55294-5","journal-title":"Sci Rep"},{"key":"2335_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultsonch.2025.107524","volume":"121","author":"W Guo","year":"2025","unstructured":"Guo W, Gao S, Hao Y, Li Z, Hu H, Wu H et al (2025) Ultrasound-responsive diagnostic and therapeutic micro-\/nanoplatforms for biomedical applications and clinical translation. Ultrason Sonochem [Internet]. 121:107524","journal-title":"Ultrason Sonochem [Internet]."},{"key":"2335_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2024.1469250","volume":"18","author":"A Singh","year":"2024","unstructured":"Singh A, Reynolds JNJ (2024) Therapeutic ultrasound: an innovative approach for targeting neurological disorders affecting the Basal Ganglia. Front Neuroanat 18:1469250","journal-title":"Front Neuroanat"},{"issue":"4","key":"2335_CR137","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/17425247.2019.1597051","volume":"16","author":"H Gholizadeh","year":"2019","unstructured":"Gholizadeh H, Cheng S, Pozzoli M, Messerotti E, Traini D, Young P et al (2019) Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. Expert Opin Drug Deliv 16(4):453\u2013466","journal-title":"Expert Opin Drug Deliv"},{"key":"2335_CR138","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/847547","volume":"2014","author":"A Naik","year":"2014","unstructured":"Naik A, Nair H (2014) Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin. Biomed Res Int 2014:847547","journal-title":"Biomed Res Int"},{"key":"2335_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060871","author":"M Singh","year":"2025","unstructured":"Singh M, Kumar S, Vinayagam R, Samivel R (2025) Thermosensitive mucoadhesive intranasal in situ gel of risperidone for nose-to-brain targeting: physiochemical and pharmacokinetics study. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph18060871","journal-title":"Pharmaceuticals (Basel)"},{"key":"2335_CR140","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-015-0222-2","volume":"3","author":"M Bourdenx","year":"2015","unstructured":"Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N et al (2015) Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by \u03b1-synuclein overexpression. Acta Neuropathol Commun 3:46","journal-title":"Acta Neuropathol Commun"},{"key":"2335_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060747","author":"IH Fl\u00f8nes","year":"2022","unstructured":"Fl\u00f8nes IH, Nyland H, Sandnes DA, Alves GW, Tysnes OB, Tzoulis C (2022) Early forms of \u03b1-synuclein pathology are associated with neuronal complex I deficiency in the Substantia Nigra of individuals with Parkinson\u2019s disease. Biomolecules. https:\/\/doi.org\/10.3390\/biom12060747","journal-title":"Biomolecules"},{"issue":"20","key":"2335_CR142","doi-asserted-by":"publisher","first-page":"29835","DOI":"10.18632\/oncotarget.8104","volume":"7","author":"SV More","year":"2016","unstructured":"More SV, Choi DK (2016) Emerging preclinical pharmacological targets for Parkinson\u2019s disease. Oncotarget 7(20):29835\u201329863","journal-title":"Oncotarget"},{"issue":"11","key":"2335_CR143","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/nn.4641","volume":"20","author":"DE Mor","year":"2017","unstructured":"Mor DE, Tsika E, Mazzulli JR, Gould NS, Kim H, Daniels MJ et al (2017) Dopamine induces soluble \u03b1-synuclein oligomers and nigrostriatal degeneration. Nat Neurosci 20(11):1560\u20131568","journal-title":"Nat Neurosci"},{"issue":"1","key":"2335_CR144","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41531-024-00781-4","volume":"10","author":"S Chevalier","year":"2024","unstructured":"Chevalier S, Decourt M, Francheteau M, Nicol F, Balbous A, Fernagut PO et al (2024) Alpha-synuclein-induced nigrostriatal degeneration and pramipexole treatment disrupt frontostriatal plasticity. NPJ Park Dis 10(1):169","journal-title":"NPJ Park Dis"},{"issue":"18","key":"2335_CR145","doi-asserted-by":"publisher","first-page":"11385","DOI":"10.1021\/acs.chemrev.0c01177","volume":"121","author":"S Correa","year":"2021","unstructured":"Correa S, Grosskopf AK, Lopez Hernandez H, Chan D, Yu AC, Stapleton LM et al (2021) Translational applications of hydrogels. Chem Rev 121(18):11385\u201311457. https:\/\/doi.org\/10.1021\/acs.chemrev.0c01177","journal-title":"Chem Rev"},{"issue":"3","key":"2335_CR146","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1021\/acs.chemrev.0c00779","volume":"121","author":"M Izci","year":"2021","unstructured":"Izci M, Maksoudian C, Manshian BB, Soenen SJ (2021) The use of alternative strategies for enhanced nanoparticle delivery to solid tumors. Chem Rev 121(3):1746\u20131803. https:\/\/doi.org\/10.1021\/acs.chemrev.0c00779","journal-title":"Chem Rev"},{"key":"2335_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031869","author":"FL Andronie-Cioara","year":"2023","unstructured":"Andronie-Cioara FL, Ardelean AI, Nistor-Cseppento CD, Jurcau A, Jurcau MC, Pascalau N et al (2023) Molecular mechanisms of neuroinflammation in aging and Alzheimer\u2019s Disease progression. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24031869","journal-title":"Int J Mol Sci"},{"key":"2335_CR148","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238948","volume":"21","author":"MC Silva","year":"2020","unstructured":"Silva MC, Haggarty SJ (2020) Tauopathies: deciphering disease mechanisms to develop effective therapies. Int J Mol Sci 21:8948","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2335_CR149","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70134","volume":"49","author":"K Casazza","year":"2026","unstructured":"Casazza K, Giugliani R, Regier DS, Jarnes J (2026) From Molecule to Meaning: Neuronopathic Biomarkers and Clinical Relevance in GM1. J Inherit Metab Dis 49(1):e70134","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2335_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00675-8","volume":"18","author":"SG Allen","year":"2023","unstructured":"Allen SG, Meade RM, White Stenner LL, Mason JM (2023) Peptide-based approaches to directly target alpha-synuclein in Parkinson\u2019s disease. Mol Neurodegener 18(1):80. https:\/\/doi.org\/10.1186\/s13024-023-00675-8","journal-title":"Mol Neurodegener"},{"issue":"1","key":"2335_CR151","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1021\/acs.jmedchem.0c00931","volume":"64","author":"A De Simone","year":"2021","unstructured":"De Simone A, Tumiatti V, Andrisano V, Milelli A (2021) Glycogen synthase kinase 3\u03b2: A new gold rush in Anti-Alzheimer\u2019s Disease multitarget drug discovery? J Med Chem 64(1):26\u201341. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00931","journal-title":"J Med Chem"},{"issue":"2","key":"2335_CR152","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s13311-021-01027-4","volume":"18","author":"AJ Schwarz","year":"2021","unstructured":"Schwarz AJ (2021) The use, standardization, and interpretation of brain imaging data in clinical trials of neurodegenerative disorders. Neurotherapeutics [Internet]. 18(2):686\u2013708","journal-title":"Neurotherapeutics [Internet]."},{"key":"2335_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212079","volume":"25","author":"JA Motyl","year":"2024","unstructured":"Motyl JA, Gromadzka G, Czapski GA, Adamczyk A (2024) SARS-CoV-2 infection and alpha-synucleinopathies: potential links and underlying mechanisms. Int J Mol Sci 25:12079","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2335_CR154","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.1021\/acs.jmedchem.3c00239","volume":"66","author":"T Liu","year":"2023","unstructured":"Liu T, Li Y, Zhang X, Yao A, Wang Y, Yao S et al (2023) Synthesis and preclinical evaluation of 2-(4-[18F]Fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([18F]FPND-4): an aza-fused tricyclic derivative as positron emission tomography tracer for neurofibrillary tangle imaging. J Med Chem [Internet] 66(14):9561\u20139576","journal-title":"J Med Chem [Internet]"},{"issue":"37","key":"2335_CR155","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk3700","volume":"10","author":"Y Jin","year":"2024","unstructured":"Jin Y, Li F, Li Z, Ikezu TC, O\u2019Leary J, Selvaraj M et al (2024) Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs. Sci Adv 10(37):eadk3700","journal-title":"Sci Adv"},{"key":"2335_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105229","volume":"149","author":"MB Thomsen","year":"2021","unstructured":"Thomsen MB, Ferreira SA, Schacht AC, Jacobsen J, Simonsen M, Betzer C et al (2021) PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiol Dis [Internet]. 149:105229","journal-title":"Neurobiol Dis [Internet]."},{"issue":"1","key":"2335_CR157","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s40478-024-01914-9","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Luo C, Jiang Y, Hu T, Lin B, Xie Y et al (2024) Decoding TDP-43: the molecular chameleon of neurodegenerative diseases. Acta Neuropathol Commun 12(1):205","journal-title":"Acta Neuropathol Commun"},{"key":"2335_CR158","doi-asserted-by":"publisher","first-page":"1671419","DOI":"10.3389\/fncel.2025.1671419","volume":"19","author":"AR Nasir","year":"2025","unstructured":"Nasir AR, Delpirou NC (2025) TDP-43-proteinopathy at the crossroads of tauopathy: on copathology and current and prospective biomarkers. Front Cell Neurosci 19:1671419","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"2335_CR159","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jnnp-2020-322983","volume":"92","author":"EMJ de Boer","year":"2020","unstructured":"de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T et al (2020) TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry 92(1):86\u201395","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2335_CR160","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s13311-022-01260-5","volume":"19","author":"LR Hayes","year":"2022","unstructured":"Hayes LR, Kalab P (2022) Emerging therapies and novel targets for TDP-43 proteinopathy in ALS\/FTD. Neurotherapeutics 19(4):1061\u20131084","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2335_CR161","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s13311-015-0338-x","volume":"12","author":"EL Scotter","year":"2015","unstructured":"Scotter EL, Chen HJ, Shaw CE (2015) TDP-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. Neurotherapeutics 12(2):352\u2013363","journal-title":"Neurotherapeutics"},{"key":"2335_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040597","author":"I Cordts","year":"2023","unstructured":"Cordts I, Wachinger A, Scialo C, Lingor P, Polymenidou M, Buratti E et al (2023) TDP-43 proteinopathy specific biomarker development. Cells. https:\/\/doi.org\/10.3390\/cells12040597","journal-title":"Cells"},{"issue":"8","key":"2335_CR163","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1021\/cr400460s","volume":"114","author":"KD Mjos","year":"2014","unstructured":"Mjos KD, Orvig C (2014) Metallodrugs in medicinal inorganic chemistry. Chem Rev 114(8):4540\u20134563. https:\/\/doi.org\/10.1021\/cr400460s","journal-title":"Chem Rev"},{"key":"2335_CR164","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.mito.2023.04.003","volume":"70","author":"RK Naviaux","year":"2023","unstructured":"Naviaux RK (2023) Mitochondrial and metabolic features of salugenesis and the healing cycle. Mitochondrion [Internet]. 70:131\u2013163","journal-title":"Mitochondrion [Internet]."},{"issue":"11","key":"2335_CR165","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.cell.2024.04.037","volume":"187","author":"A Suomalainen","year":"2024","unstructured":"Suomalainen A, Nunnari J (2024) Mitochondria at the crossroads of health and disease. Cell [Internet]. 187(11):2601\u20132627","journal-title":"Cell [Internet]."},{"issue":"1","key":"2335_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s12993-025-00279-w","volume":"21","author":"DD \u00c1lvarez-Luqu\u00edn","year":"2025","unstructured":"\u00c1lvarez-Luqu\u00edn DD, Gonz\u00e1lez-Fern\u00e1ndez RR, Torres-Velasco ME, Ichikawa-Escamilla E, Arce-Sillas A, Mart\u00ednez-Mart\u00ednez E et al (2025) Neurodegeneration models in Parkinson\u2019s disease: cellular and molecular paths to neuron death. Behav Brain Funct 21(1):14","journal-title":"Behav Brain Funct"},{"key":"2335_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/cells14151161","author":"M Tanaka","year":"2025","unstructured":"Tanaka M (2025) Parkinson\u2019s Disease: bridging gaps, building biomarkers, and reimagining clinical translation. Cells. https:\/\/doi.org\/10.3390\/cells14151161","journal-title":"Cells"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02335-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02335-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02335-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:38:40Z","timestamp":1786426720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02335-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":167,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2335"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02335-6","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"164"}}